<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Schedule 13G
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. __)
PharmaPrint Inc.
-------------------------------------------
(Name of Issuer)
Common Stock, no par value per share
-------------------------------------------
(Title of Class of Securities)
980102
-------------------------------------------
(CUSIP Number)
- ----------------
The remainder of this cover page shall be filled out for a reporting person's
initial filing of this form with respect to the subject class of securities,
and for any subsequent amendment containing information which could alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
Page 1 of 6
<PAGE>
- ---------------- -----------------
CUSIP No. 890102 13G Page 2 of 6 Pages
- ---------------- -----------------
- ------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Tasneem A. Khwaja, Ph.D.
- ------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- ------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
California
- ------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 2,803,000
BENEFICIALLY ----------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 0
PERSON ----------------------------------------------------------------
WITH 7 SOLE DISPOSITIVE POWER
2,803,000
----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
- ------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,803,000
- ------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES*
- ------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
25.5%
- ------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
- ------------------------------------------------------------------------------
<PAGE>
- ---------------- -----------------
CUSIP No. 980102 13G Page 3 of 6 Pages
- ---------------- -----------------
Item 1(a). Name of Issuer:
PharmaPrint, Inc. (the "Company")
Item 1(b). Address of Issuer's Principal Executive Offices:
4 Park Plaza, Suite 1900, Irvine, California 92614
Item 2(a). Name of Person Filing:
Tasneem A. Khwaja, Ph.D.
Item 2(b). Address of Principal Business Office or, if None, Residence:
4 Park Plaza, Suite 1900, Irvine, California 92614
Item 2(c). Citizenship:
California
Item 2(d). Title of Class of Securities:
Common Stock, no par value per share, of the Company ("Common
Stock")
Item 2(e). CUSIP Number:
980102
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b), check whether the person filing is a:
Not applicable.
Item 4. Ownership.
(a) Amount beneficially owned:
2,803,000
<PAGE>
- ---------------- -----------------
CUSIP No. 980102 13G Page 4 of 6 Pages
- ---------------- -----------------
(b) Percent of Class:
25.5%
(c) Number of shares to which such person has:
(i) Sole power to vote or direct the vote:
2,803,000
(ii) Shared power to vote or direct the vote:
0
(iii) Sole power to dispose or to direct the disposition
of:
2,803,000
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported By the Parent Holding
Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
<PAGE>
- ---------------- ------------------
CUSIP No. 980102 13G Pages 5 of 6 Pages
- ---------------- ------------------
Item 9. Notice of Dissolution of a Group.
Not applicable
Item 10. Certification.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired in the ordinary
course of business and were not acquired for the purpose of and do not have
the effect of changing or influencing the control of the Company and were
not acquired in connection with or as a participant in any transaction having
such purpose or effect.
<PAGE>
- ---------------- -----------------
CUSIP No. 980102 13G Page 6 of 6 Pages
- ---------------- -----------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: February 14, 1997
----------------------------------
/s/ Tasneem A. Khwaja, Ph.D.
---------------------------------------
Tasneem A. Khwaja, Ph.D.
